Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

13.60 -0.33 (-2.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a... 
Via Stocktwits
Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial
Amylyx ends its PSP trial for AMX0035 after no efficacy was seen and turns its focus to avexitide and ALS research, expecting data in 2025 and 2026. 
Via Benzinga
Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder
Via Stocktwits
Amylyx (AMLX) Q2 Net Loss Narrows 43%
Via The Motley Fool
Topics Intellectual Property
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Q2 2025 Earnings: EPS In Line, Revenue at $0, Market Reaction Muted
Amylyx Pharmaceuticals reports Q2 2025 earnings with EPS in line, $41.4M net loss. Market reaction muted as focus remains on clinical-stage pipeline updates. 
Via Chartmill
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Exploring Amylyx Pharma's Earnings Expectations
 
Via Benzinga
4 Analysts Assess Amylyx Pharma: What You Need To Know
 
Via Benzinga
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia. 
Via Benzinga
Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial
The company is advancing the treatment into a Phase 3 study with results expected in 2026. 
Via Stocktwits
Why Shares in Amylyx Pharmaceuticals Soared This Week
Via The Motley Fool
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity. 
Via Benzinga
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Analyst Ratings For Amylyx Pharma
 
Via Benzinga
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
 
Via Benzinga
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
 
Via Benzinga
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
 
Via Benzinga
6 Analysts Assess Amylyx Pharma: What You Need To Know
 
Via Benzinga
Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
 
Via Benzinga
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For March 4, 2025
 
Via Benzinga
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November
 
Via Benzinga
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder. 
Via The Motley Fool
Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying
 
Via Benzinga
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.